Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA Complementary DNA (cDNA) by the EFS-ADA Lentiviral Vector for Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency (ADA-SCID)

Next Previous
Trial Profile

Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA Complementary DNA (cDNA) by the EFS-ADA Lentiviral Vector for Severe Combined Immunodeficiency Due to Adenosine Deaminase Deficiency (ADA-SCID)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Simoladagene autotemcel (Primary) ; Busulfan; Elapegademase
  • Indications Adenosine deaminase deficiency
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms UCLA Fresh Study
  • Sponsors Orchard Therapeutics

Most Recent Events

  • 11 May 2021 Results (n=50) from NCT01852071, NCT02999984, and NCT01380990 assessing overall and event-free survival in autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency, published in the New England Journal of Medicine
  • 11 May 2021 Data from three Phase 1/2 clinical studies (n=40), and a compassionate use program (n=10) presented in an Orchard Media Release.
  • 11 May 2021 According to an Orchard Therapeutics media release, data from three Phase 1/2 clinical studies (n=40), and a compassionate use program (n=10) published in the New England Journal of Medicine (NEJM) .

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top